Patent
Attorney Docket: 266/187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Neil H. Bander

Serial No.: Not yet assigned

Filed: Herewith

(CONTINUATION OF S.N. 09/357,704 FILED JULY 20, 1999 (Atty. 242/024))

For: Treatment and Diagnosis of Prostate Cancer

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION
Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the specification by adding the relate-back information. Replace the first paragraph on page 1, beginning at line 3, with the following:

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EL360933793US
Express Mail Label No.

August 13, 2001
Date of Deposit

Felicia Reyes
Name of Person Mailing Paper

Felicia Reyes
Signature of Person Mailing Paper

This application is a Continuation Application of Application Serial No. 09/357,704, filed on July 20, 1999; which is a Divisional of Application Serial No. 08/838,682, filed on April 9, 1997; which claims the benefit of U.S. Provisional Patent Application Serial No. 60/016,976, filed May 6, 1996, and U.S. Provisional Patent Application Serial No. 60/022,125, filed July 18, 1996.

IN THE CLAIMS:

Please cancel claims 1 - 67 from the prior application.

Please add the following claims 68 - 82:

68. An isolated antibody or binding portion thereof which competes with an antibody selected from the group consisting of E99, J415, J533 and J591 for binding to the extracellular domain of prostate specific membrane antigen.

69. The antibody or binding portion of claim 68, which is a monoclonal antibody or binding portion thereof.

70. The antibody or binding portion of claim 68, which is selected from the group consisting of a Fab fragment, a $F(ab)'_2$ fragment, and an Fv fragment.

71. The antibody or binding portion of claim 68, which is an IgG antibody.

72. The antibody or binding portion thereof of claim 68, which is bound to a drug.

73. The antibody or binding portion thereof of claim 72, wherein the drug is a cytotoxic drug.

74. The antibody or binding portion thereof of claim 73, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation, molecules of plant, fungal, or bacterial origin, biological protein, and mixtures thereof.

75. The antibody or binding portion thereof of claim 68, which is bound to a label.

76. The antibody or binding portion thereof of claim 73, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance label, a luminescent label, and a chromophore label.

77. A composition comprising the antibody or binding portion thereof of claim 68 or 72 and a physiologically acceptable carrier.

78. A composition comprising the antibody or binding portion thereof of claim 68 or 72 and a pharmaceutically acceptable carrier.

79. A kit for detecting prostate cancer comprising the antibody or binding portion thereof of claim 75 and means to detect the label.

80. A method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells comprising contacting said cells with the antibody or binding portion thereof of claim 68 or 72 under conditions effective to permit ablating or killing of said cells.

81. The method of claim 76, wherein the contacting is carried out in a living mammal and comprises administering the antibody or binding portion thereof to the mammal under conditions effective to permit ablating or killing of said cells.

82. The method of claim 81, wherein the antibody or binding portion thereof is administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitory or intravesical instillation, intraarterially, intralesionally, or by application to mucous membranes.

Respectfully submitted,

LYON & LYON LLP

Dated: August 13, 2001

By: 
Lois M. Kwasigroch
Reg. No. 35,579

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

MARKED UP VERSION TO SHOW CHANGES MADE IN SPECIFICATION

On page 1, the first paragraph beginning at line 3:

This application is a Continuation Application of Application Serial No. 09/357,704, filed on July 20, 1999; which is a Divisional of Application Serial No. 08/838,682, filed on April 9, 1997; which [The present application] claims the benefit of U.S. Provisional Patent Application Serial No. 60/016,976, filed May 6, 1996, and U.S. Provisional Patent Application Serial No. 60/022,125, filed July 18, 1996.